Biomarin Pharmaceutical News and Activities

Biomarin Pharmaceutical is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Biomarin Pharmaceutical is a company listed under the stock ticker BMRN (US).

Biomarin Pharmaceutical has a direct presence in 5 countries.

Biomarin Pharmaceutical has 6 subsidiaries including Amicus Therapeutics, Amicus Therapeutics France and Amicus Therapeutics Germany.

They are in:

• Biotechnology86%
• Pharmaceuticals14%

Acquisition, funding and merger involving Biomarin Pharmaceutical.

• Biomarin Pharmaceutical has acquired Amicus Therapeutics (posted on April 27 2026).
• Biomarin Pharmaceutical has just announced a $82 Million fundraising (posted on January 30 2026).
• Biomarin Pharmaceutical has announced the acquisition of Amicus Therapeutics  (posted on December 22 2025).
• Biomarin Pharmaceutical has announced the acquisition of Inozyme  (posted on May 29 2025).
• See more news about Biomarin Pharmaceutical Hide news involving Biomarin Pharmaceutical

View the org chart displaying its 60 main executives

Most searched biographies at Biomarin Pharmaceutical

• Alexander Hardy, Chief Executive Officer and President
• Willard Dere, Director
• Robert Hombach, Director

Popular executive movements at Biomarin Pharmaceutical

• Richard Meier, Chairman of the Board, will retire on Jun. 2, 2026  (posted on April 22 2026).
• Ian Clark who is Director, will become Chairman of the Board on Jun. 2, 2026  (posted on April 22 2026).
• Arpit Davé has joined the company as Chief Digital and Information Officer  (posted on January 13 2026).

Create your alert
to follow the executive moves at Biomarin Pharmaceutical.

Biomarin Pharmaceutical has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Biomarin Pharmaceutical

• BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia
• BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
• BioMarin Reports First Quarter 2026 Financial and Operating Results
• BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting
• BioMarin Completes Acquisition of Amicus Therapeutics
• BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
• BioMarin Announces Board Leadership Transition
• BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genet
• Company Statements | BioMarin
• U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
• View more press releases Close

Social media about Biomarin Pharmaceutical

• Biomarin Pharmaceutical on Wikipedia, Google News & Yahoo Finance
• Biomarin Pharmaceutical on LinkedIn, X (Twitter) & YouTube